logo
  

Identiv, Inc. Q1 Loss increases, misses estimates

Identiv, Inc. (INVE) announced Loss for its first quarter that increased from last year and missed the Street estimates.

The company's earnings came in at -$4.56 million, or -$0.21 per share. This compares with -$2.72 million, or -$0.13 per share, in last year's first quarter.

Analysts on average had expected the company to earn -$0.13 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 13.5% to $22.49 million from $26.00 million last year.

Identiv, Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$4.56 Mln. vs. -$2.72 Mln. last year.
-EPS (Q1): -$0.21 vs. -$0.13 last year.
-Revenue (Q1): $22.49 Mln vs. $26.00 Mln last year.

For comments and feedback contact: editorial@rttnews.com

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT